Cargando…
Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer
Epigenetic deregulation plays an essential role in hepatocellular carcinoma (HCC) progression. Bromodomains are epigenetic “readers” of histone acetylation. Recently, bromodomain inhibitors have exhibited promising therapeutic potential for cancer treatment. Using transcriptome sequencing, we identi...
Autores principales: | Cheng, Carol Lai-Hung, Tsang, Felice Hoi-Ching, Wei, Lai, Chen, Mengnuo, Chin, Don Wai-Ching, Shen, Jialing, Law, Cheuk-Ting, Lee, Derek, Wong, Carmen Chak-Lui, Ng, Irene Oi-Lin, Wong, Chun-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292510/ https://www.ncbi.nlm.nih.gov/pubmed/34285329 http://dx.doi.org/10.1038/s42003-021-02405-6 |
Ejemplares similares
-
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
por: Wei, Lai, et al.
Publicado: (2019) -
GSK6853, a Chemical Probe for Inhibition of the BRPF1
Bromodomain
por: Bamborough, Paul, et al.
Publicado: (2016) -
The BRPF1 bromodomain is a molecular reader of di-acetyllysine
por: Obi, Juliet O., et al.
Publicado: (2020) -
In Vivo Genome-Wide CRISPR Activation Screening Identifies Functionally Important Long Noncoding RNAs in Hepatocellular Carcinoma
por: Wong, Lok-Sze, et al.
Publicado: (2022) -
Discovery of a
Chemical Tool Inhibitor Targeting the
Bromodomains of TRIM24 and BRPF
por: Bennett, James, et al.
Publicado: (2015)